Researchers are coaxing the eye to become a biofactory to make its own anti-VEGF medications. This month's feature provides an overview of the leading AAV-based contenders.
Don't miss the EyeNet Corporate Lunches on Saturday, Sunday, and Monday.
Put your patients on the path toward
helping to manage their vision
© 2022, Regeneron Pharmaceuticals, Inc.
All rights reserved.
Publications for This Year's AAO
News in Review